Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABUS NASDAQ:AGIO NYSE:BHC NASDAQ:GMTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABUSArbutus Biopharma$3.13-0.3%$3.30$2.71▼$4.73$599.48M1.2951,088 shs894,105 shsAGIOAgios Pharmaceuticals$40.00-0.9%$33.85$23.42▼$62.58$2.32B0.73658,004 shs824,551 shsBHCBausch Health Cos$6.31-2.6%$5.60$3.96▼$9.85$2.34B0.412.53 million shs902,877 shsGMTXGemini Therapeutics$57.770.0%$51.05$1.16▼$14.10$2.50B-0.12189,291 shs672,319 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABUSArbutus Biopharma0.00%-1.26%-9.80%-0.63%-17.20%AGIOAgios Pharmaceuticals0.00%+2.43%+12.68%+44.61%-15.18%BHCBausch Health Cos0.00%-1.87%+1.89%+23.12%-17.19%GMTXGemini Therapeutics-0.03%+1.51%+15.33%+37.01%+20.56%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABUSArbutus Biopharma1.5696 of 5 stars3.50.00.00.00.62.50.6AGIOAgios Pharmaceuticals4.3855 of 5 stars3.43.00.04.32.30.81.9BHCBausch Health Cos3.4859 of 5 stars1.94.00.04.00.63.30.6GMTXGemini TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABUSArbutus Biopharma 3.00Buy$5.5075.72% UpsideAGIOAgios Pharmaceuticals 2.71Moderate Buy$58.6046.50% UpsideBHCBausch Health Cos 1.83Reduce$7.3015.69% UpsideGMTXGemini Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ABUS, GMTX, BHC, and AGIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/2/2025AGIOAgios PharmaceuticalsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$74.00 ➝ $71.005/2/2025BHCBausch Health CosRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$8.50 ➝ $10.00(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABUSArbutus Biopharma$6.17M97.16N/AN/A$0.51 per share6.14AGIOAgios Pharmaceuticals$36.50M63.47N/AN/A$27.02 per share1.48BHCBausch Health Cos$9.63B0.24$7.70 per share0.82($0.89) per share-7.09GMTXGemini TherapeuticsN/AN/AN/AN/A$2.89 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABUSArbutus Biopharma-$69.92M-$0.41N/AN/AN/A-1,196.64%-75.51%-55.81%8/7/2025 (Estimated)AGIOAgios Pharmaceuticals$673.72M$11.243.56N/AN/A1,798.26%-2.75%-2.52%7/31/2025 (Estimated)BHCBausch Health Cos-$46M-$0.11N/A1.35N/A-0.41%-540.45%5.26%7/30/2025 (Estimated)GMTXGemini Therapeutics-$71.87M-$1.00N/AN/AN/AN/A-38.78%-35.88%N/ALatest ABUS, GMTX, BHC, and AGIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025ABUSArbutus Biopharma-$0.02N/AN/AN/AN/AN/A7/31/2025Q2 2025AGIOAgios Pharmaceuticals-$1.74N/AN/AN/A$9.46 millionN/A7/30/2025Q2 2025BHCBausch Health Cos$0.9320N/AN/AN/A$2.47 billionN/A5/14/2025Q1 2025ABUSArbutus Biopharma-$0.09-$0.13-$0.04-$0.13$2.54 million$1.76 million5/1/2025Q1 2025AGIOAgios Pharmaceuticals-$1.80-$1.55+$0.25-$1.55$9.86 million$8.73 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABUSArbutus BiopharmaN/AN/AN/AN/AN/AAGIOAgios PharmaceuticalsN/AN/AN/AN/AN/ABHCBausch Health CosN/AN/AN/AN/AN/AGMTXGemini TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABUSArbutus Biopharma0.046.016.01AGIOAgios PharmaceuticalsN/A18.5017.93BHCBausch Health CosN/A1.350.97GMTXGemini TherapeuticsN/A71.4971.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABUSArbutus Biopharma43.79%AGIOAgios PharmaceuticalsN/ABHCBausch Health Cos78.65%GMTXGemini Therapeutics75.42%Insider OwnershipCompanyInsider OwnershipABUSArbutus Biopharma20.30%AGIOAgios Pharmaceuticals4.30%BHCBausch Health Cos8.05%GMTXGemini Therapeutics12.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABUSArbutus Biopharma90191.53 million152.65 millionOptionableAGIOAgios Pharmaceuticals39057.92 million55.43 millionOptionableBHCBausch Health Cos20,700370.08 million340.29 millionOptionableGMTXGemini Therapeutics3043.33 million37.74 millionNot OptionableABUS, GMTX, BHC, and AGIO HeadlinesRecent News About These CompaniesGemini Therapeutics (NASDAQ:GMTX) Stock Price Down 1.9% - Should You Sell?July 15, 2025 | marketbeat.comWhat Is Gemini? Everything You Should Know About Google's AI ToolOctober 17, 2024 | cnet.comGoogle Gemini could soon get a lot more useful on your phoneJuly 31, 2024 | androidpolice.comAGemini Review 2024: Is This Crypto Exchange a Gem for Your Investments?July 22, 2024 | businessinsider.comChatGPT vs. Microsoft Copilot vs. Gemini: Which is the best AI chatbot?May 23, 2024 | zdnet.comZGemini Monthly Horoscope: May 2024May 2, 2024 | pedestrian.tvPGoogle's Gemini AI Will Work On Your Pixel 2 XL—Android 10, 11 Devices Now SupportedApril 28, 2024 | techtimes.comTComparing ChatGPT 3.5, Microsoft Bing, and Google Gemini in diagnosing cases of neuro-ophthalmologyApril 17, 2024 | ophthalmologytimes.comOGoogle's public release of Gemini 1.5 should build trust, Deutsche Bank saysApril 17, 2024 | seekingalpha.comGoogle takes down Gemini AI image generator. Here’s what you need to know.February 26, 2024 | washingtonpost.com‘White privilege is f–king real’: Google Gemini product lead’s old tweets allegedly resurface amid ‘woke’ AI image fiascoFebruary 26, 2024 | nypost.comNGoogle Gemini: Everything you need to know about Google's Answer to ChatGPT – Updated December 2023December 9, 2023 | androidheadlines.comAGemini Review 2023: Pros, Cons and How It ComparesNovember 16, 2023 | nerdwallet.comNYesterday's Gemini HoroscopeOctober 5, 2023 | yourtango.comYGemini Tarot Horoscopes: October 2023October 3, 2023 | glamour.comGYearly Gemini Tarot Card ReadingAugust 28, 2023 | yourtango.comYMove over Bard, Google's next big AI product is coming this fallAugust 19, 2023 | androidauthority.comARadar In Space: The Gemini Rendezvous RadarJuly 27, 2023 | hackaday.comHSun Transit in Gemini- The twins love the Sun’s visitJuly 13, 2023 | prokerala.comPSun Transit in Gemini: Sun with Dual energies?July 5, 2023 | prokerala.comPGemini Allows Withdrawals for Voyager Customers Whose Funds Have Been Trapped since BankruptcyJune 26, 2023 | coinspeaker.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeABUS, GMTX, BHC, and AGIO Company DescriptionsArbutus Biopharma NASDAQ:ABUS$3.13 -0.01 (-0.32%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$3.16 +0.03 (+0.96%) As of 07/18/2025 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.Agios Pharmaceuticals NASDAQ:AGIO$40.00 -0.35 (-0.87%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$40.29 +0.29 (+0.73%) As of 07/18/2025 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Bausch Health Cos NYSE:BHC$6.31 -0.17 (-2.62%) Closing price 07/18/2025 03:59 PM EasternExtended Trading$6.42 +0.11 (+1.81%) As of 07/18/2025 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.Gemini Therapeutics NASDAQ:GMTX$57.77 -0.02 (-0.03%) As of 07/18/2025Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
